ArticleGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2026
Clinical exit strategy in anti-VEGF therapy for neovascular AMD: incidence of recurrence and risk factors for relapse.
Article in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the recurrence rate of neovascular activity after discontinuation of intravitreal anti-vascular endothelial growth factor (VEGF) therapy in patients with neovascular age-related macular degeneration (AMD) and to identify baseline clinical and imaging factors associated with relapse following a clinical exit strategy.
methodsIn this retrospective cohort study, patients with neovascular AMD who discontinued anti-VEGF therapy due to a clinical decision were identified. Treatment discontinuation was based on the absence of foveal exudation on optical coherence tomography (OCT). Baseline demographic, clinical, and OCT characteristics were analyzed. The primary outcome was disease recurrence, defined as the need for a new intravitreal anti-VEGF injection during follow-up. Multivariate regression analysis was performed to identify baseline biomarkers associated with relapse.
resultsSeventy-eight patients (78 eyes) were included (mean age 82.3 ± 5.5 years; 78.2% women). Disease recurrence occurred in 38 patients (48.7%) after a mean of 389.0 ± 247.3 days, with 47.4% of relapses occurring within the first year. Visual acuity significantly worsened between treatment discontinuation and relapse (p < 0.001). At the time of retreatment, intraretinal fluid, subretinal fluid, and subretinal hyperreflective material were observed in 57.9%, 63.2%, and 55.3% of eyes, respectively. Multivariate regression identified extrafoveal intraretinal fluid and retinal pigment epithelium tear at baseline as biomarkers associated with recurrence.
conclusionsRecurrence after anti-VEGF discontinuation is common in neovascular AMD. The presence of extrafoveal intraretinal fluid and retinal pigment epithelium tear at treatment cessation may increase the risk of relapse, highlighting the need for cautious treatment exit strategies and close post-discontinuation monitoring.
Indexed as
Identifiers
42850327What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.